Previous 10 | Next 10 |
Aytu BioScience (NASDAQ: AYTU ) rises ~8% in premarket, after the company announces to manufacture and deliver Healight investigational devices, for use in upcoming COVID-19 clinical studies. The device is designed by Sterling Medical Devices. More news on: Aytu B...
Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 Patients ENGLEWOOD, CO / ACCESSWIRE / August 17, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company...
FinancialBuzz.com News Commentary New York, NY (8/12/2020) – As the pandemic continues to spread throughout the U.S., the need for testing is on the rise as well. But many states and regions are experiencing a shortage of tests, which is a serious obstacle to the fight against the sprea...
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...
Aytu BioScience's Sublicensee SUDA Pharmaceuticals Secures TGA Approval, Enabling Near-Term Commercialization of ZolpiMist ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing nove...
FinancialBuzz.com News Commentary New York, NY (7/28/2020) – The pandemic continues to devastate the economy as well as healthcare systems around the world. In response to the outbreak, governments have focused their resources on treatment and prevention. Besides the esearch necessary t...
FinancialBuzz.com News Commentary New York, NY (7/27/2020) – The wearable technology ecosystem continues to rapidly evolve around the world as several technological developments help stir up demand. The medical technology sector, among others such as biotechs developing vaccines and med...
Article Reports Results from Independent Study Demonstrating Test's 100% Sensitivity and Specificity for IgM Antibodies and 96.7% and 97.5% Sensitivity and Specificity, Respectively, for IgG Antibodies ENGLEWOOD, CO / ACCESSWIRE / July 27, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a spe...
Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States ENGLEWOOD, CO / ACCESSWIRE / July 20, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commer...
FinancialBuzz.com News Commentary New York, NY (7/13/2020) – In a time of a pandemic, new innovations solutions to health problems are in need. One group of devices that got more attention as a result are wearable devices. The growing popularity of the Internet of Things (IoT) and conne...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...